Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders-A Scoping Review.
Level 5 - mechanism / opinion, no new human data
Scoping review synthesizing heterogeneous preclinical, clinical, and mechanistic literature.
PubMed 41683522 · doi:10.3390/molecules31030545
What was done
The authors conducted a scoping review synthesizing published preclinical and clinical literature on ibogaine for the treatment of substance use disorders. The review evaluated reported effects on substance withdrawal symptoms, drug craving, dose-response relationships, and the occurrence of cardiac adverse events.
What was found
The abstract reports no numerical findings or quantitative effect estimates. It notes that ibogaine exhibits a multimodal neuropharmacological profile that supports a hypothesized neurobiological reset across multiple addiction pathways, but emphasizes that evidence remains fragmented and constrained by significant cardiac safety concerns and lack of standardized formulations.
Why it matters
This review outlines the therapeutic rationale and translational roadblocks for ibogaine, framing the key toxicological and regulatory requirements needed before it can be safely developed for addiction treatment.
Limits
The abstract provides no study counts, sample sizes, or specific quantitative outcome measures. The underlying literature base is heterogeneous and limited by cardiac toxicity risks, lack of regulatory standardization, and reliance on early-stage or preclinical evidence.
Cited by
- context Ibogaine eliminates substance addiction in a single administration.